XCL1 could mitigate psychiatric condition risk in offspring 29 April 2024 | By Drug Target Review Adult anxious behaviour in offspring may be related to the early life proinflammatory state caused by the absence of elevated XCL1.
Accelerating cardiac regenerative therapy with HiPSC spheroids 29 April 2024 | By Drug Target Review Injections of cardiac spheroids into primate ventricles improved left ventricular ejection after four weeks.
Carbohydrate-based vaccine combats Staphylococcus aureus 26 April 2024 | By Drug Target Review In animal studies, the new vaccine construct outperformed another PNAG-vaccine delivery system currently in human trials.
How tumours prevent formation of immune responses 25 April 2024 | By Drug Target Review Scientists found that preventing the effects of prostaglandin E2 could be an effective therapy to overcome tumour defence.
Mini-colons reveal complex process of tumorigenesis ex vivo 25 April 2024 | By Drug Target Review The mini-colons are topobiologically complex, can be induced to develop tumours in targeted areas and reduce the use of animal models.
New findings regarding diabetes risk in childhood cancer survivors 24 April 2024 | By Drug Target Review Four previously unknown genetic variants provide a new understanding of differences in risk between individuals of varying ancestries.
New single-cell lipidomics method may unlock cancer treatments 24 April 2024 | By Drug Target Review A new method for a fragmentation-based identification of lipids could enable the study of cancer cells in detail not seen before.
Exploring the role of class IIa HDACs in inflammatory diseases 23 April 2024 | By Drug Target Review The pharmacological inhibition of class IIa HDACs could be a therapeutic approach for addressing Th17-related inflammatory and autoimmune diseases.
The effect of ovarian stimulation on IVF outcomes 23 April 2024 | By Drug Target Review In mouse models, the differences between oocytes collected by natural or stimulated approaches were investigated.
Targeting RAS to overcome FLT3 AML drug resistance 22 April 2024 | By Drug Target Review It was discovered that targeting RAS proteins prevent cancer cells from using different signalling pathways to escape cell death.
Mitochondrial depletion results in abnormal protein accumulation 22 April 2024 | By Drug Target Review Researchers find the mechanism which may underly the onset and progression of age-related neurodegenerative diseases.
Evaluating the anti-obesity effects of tocotrienols 19 April 2024 | By Drug Target Review The new study found T3s treatment exhibited neuroprotective effects in HFSD-fed mice by mitigating oxidative stress.
Zyme Communications expand their UK headquarters 19 April 2024 | By Drug Target Review The move to Cambridge Innovation Park reflects the continued growth of Zyme's internal team and client network.
Drug-loaded 3D printed films could revolutionise liver cancer treatment 18 April 2024 | By Drug Target Review The new films killed over 80 percent of cancer cells, reduced recurrence rates and minimised undesirable chemotherapy side effects.
Explaining uveal melanoma’s resistance to conventional immunotherapies 17 April 2024 | By Drug Target Review Researchers have developed a new tool called ‘Uveal Melanoma Immunogenic Score’ to predict which patients will respond to adoptive therapy.
